The hypothesis that stimulant medications may cause growth deficits in children with attention deficit hyperactivity disorder (ADHD) was reevaluated in 124 children and adolescents with ADHD and 109 controls at the Massachusetts General Hospital, Boston, MA. Small, significant deficits in height (average, 3 cm) were found in early but not late adolescent ADHD children, and height deficits were unrelated to weight deficits or stimulant treatment. In 10% of ADHD children cf 1% of controls, height deficits were more than 2 standard deviations (approx 14 cm in 15-yr-old males) below the average height of controls. The larger growth deficits occurred in patients with comorbid major depression but not in those with anxiety disorders. Neither recent nor past history of stimulant therapy significantly affected height measures in either early or late pubertal ADHD children. Pubertal development and weight measures of ADHD children were not different from controls. (Spencer TJ, Biederman J, Harding M, O'Donnell D, Faraone SV, Wilens TE. Growth deficits in ADHD children revisited: evidence for disorderassociated growth delays? 1
ATTENTION DEFICIT DISORDERS GROWTH AND WEIGHT DEFICITS IN ADHD
The hypothesis that stimulant medications may cause growth deficits in children with attention deficit hyperactivity disorder (ADHD) was reevaluated in 124 children and adolescents with ADHD and 109 controls at the Massachusetts General Hospital, Boston, MA. Small, significant deficits in height (average, 3 cm) were found in early but not late adolescent ADHD children, and height deficits were unrelated to weight deficits or stimulant treatment. In 10% of ADHD children cf 1% of controls, height deficits were more than 2 standard deviations (approx 14 cm in 15-yr-old males) below the average height of controls. The larger growth deficits occurred in patients with comorbid major depression but not in those with anxiety disorders. COMMENT. ADHD may be associated with a temporary delay in the rate of growth in height in early adolescence that may be corrected by late adolescence. ADHD-associated height deficits are unrelated to stimulantassociated weight loss and may represent a manifestation of ADHD, mediated by a maturational delay. The dysmaturity hypothesis of ADHD, usually confined to neurobehavioral and attentional deficits, may be extended to physical deficits that can be outgrown. Small weight deficits in some ADHD children receiving stimulant therapy can usually be offset by adjusting the timing of medication and by food supplements if indicated.
In a Northwestern University, prospective study of the growth of 36 boys with ADHD, 5 to 10 years of age, who were treated with methylphenidate, PEDIATRIC 1996;98:763-769) . Using body mass index as a measure, pretreatment weight was a significant predictor of stimulant-related weight loss, heavier children losing more weight than thinner children. In overweight ADHD children, stimulant medication may provide a secondary benefit, improving self-esteem.
METHYLPHENIDATE DOSING SCHEDULES
Efficacy and side effects of twice daily (bid) and three times daily (tid) methylphenidate (MPH) dosing schedules (mean dose, 8 mg, 0.3 mg/kg) in 25 boys with attention deficit hyperactivity disorder (ADHD) were compared in a 5-week, placebo-controlled, crossover COMMENT. This short term study shows that more frequent, smaller dose, three times daily MPH treatment is often preferable to twice daily dosing schedules. The incidence of insomnia, usually regarded as a disadvantage of afternoon doses, is not increased, and teacher and parent ratings of MPH efficacy are benefited. Doses of MPH for ADHD should be selected for each individual child according to the time of occurrence of symptoms and not with regard to the pattern of possible side effects. An evening free from parentchild conflict and a home-work assignment satisfactorily completed may lead to improved self esteem and better classroom performance. Closer monitoring of MPH dosing schedules, using both parent and teacher abbreviated reports, should result in optimal treatment efficacy.
The benefits of a group treatment developmental approach, involving patients and their families, as a supplement to medication, are reported from the Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, CA. (Lock J. Developmental considerations in the treatment of school-age boys with ADHD: an example of a group treatment approach. J Am Acad Child Adolesc Psychiatry Nov 1996;35:1557-1559).
CARDIOVASCULAR EFFECTS OF TRICYCLIC ANTIDEPRESSANTS
Twenty-four pediatric studies, published from various centers between
